Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors

James L Bockhorst; Iyad Ksseiry; Maripat Toye; Stuart R Chipkin; Barbara W Stechenberg; Donna J Fisher; Holley F Allen

Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors

Pediatr Infect Dis J. 2003 May;22(5):463-5.

Authors

James L Bockhorst¹, Iyad Ksseiry, Maripat Toye, Stuart R Chipkin, Barbara W Stechenberg, Donna J Fisher, Holley F Allen

Affiliation

¹ Department of Medicine, Baystate Medical Center, 759 Chestnut Street, Springfield, MA 01199, USA.

PMID: 12797313

Abstract

We conducted a prospective evaluation for evidence of the HIV-associated lipodystrophy syndrome of 26 children infected with HIV-1. Six children had evidence of body fat redistribution. Nine children showed laboratory evidence of insulin resistance. All children with body fat distribution or insulin resistance had been treated with protease inhibitors. Children treated with protease inhibitors had higher total cholesterol, higher low density lipoprotein-cholesterol and higher triglycerides than untreated children.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Analysis of Variance
Body Composition
Body Mass Index
CD4 Lymphocyte Count
Child
Child, Preschool
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
HIV-1 / drug effects*
HIV-1 / isolation & purification
HIV-Associated Lipodystrophy Syndrome / diagnosis*
HIV-Associated Lipodystrophy Syndrome / drug therapy*
HIV-Associated Lipodystrophy Syndrome / epidemiology
Humans
Incidence
Insulin Resistance
Lipoproteins, HDL / analysis
Lipoproteins, HDL / drug effects
Male
Probability
Prognosis
Prospective Studies
Protease Inhibitors / administration & dosage*
Risk Assessment
Sampling Studies
Severity of Illness Index
Treatment Outcome

Substances

Lipoproteins, HDL
Protease Inhibitors